NOT FOR DISTRIBUTION
Header cover image

Market Cap

CN¥49.3b

Last Updated

2021/04/11 09:04 UTC

Data Sources

Company Financials

Executive Summary

Shanghai RAAS Blood Products Co., Ltd. manufactures and distributes blood products in China and internationally. More Details


Snowflake Analysis

Flawless balance sheet with proven track record.


Similar Companies

Share Price & News

How has Shanghai RAAS Blood Products's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: 002252 is less volatile than 75% of CN stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: 002252's weekly volatility (4%) has been stable over the past year.


Market Performance


7 Day Return

-1.9%

2252

2.5%

CN Biotechs

-1.1%

CN Market


1 Year Return

-7.8%

2252

39.3%

CN Biotechs

28.4%

CN Market

Return vs Industry: 002252 underperformed the CN Biotechs industry which returned 35.6% over the past year.

Return vs Market: 002252 underperformed the CN Market which returned 27.4% over the past year.


Shareholder returns

2252IndustryMarket
7 Day-1.9%2.5%-1.1%
30 Day-4.9%9.2%1.0%
90 Day2.2%0.3%-5.8%
1 Year-7.7%-7.8%39.8%39.3%30.4%28.4%
3 Yearn/a80.7%78.0%25.9%19.9%
5 Year-64.4%-64.6%61.2%58.2%23.6%15.5%

Long-Term Price Volatility Vs. Market

How volatile is Shanghai RAAS Blood Products's share price compared to the market and industry in the last 5 years?


Simply Wall St News

No news available

Valuation

Is Shanghai RAAS Blood Products undervalued compared to its fair value and its price relative to the market?

40.62x

Price to Earnings (PE) ratio


Share Price vs. Fair Value

Below Fair Value: 002252 (CN¥7.32) is trading above our estimate of fair value (CN¥3.62)

Significantly Below Fair Value: 002252 is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: 002252 is good value based on its PE Ratio (40.6x) compared to the CN Biotechs industry average (56x).

PE vs Market: 002252 is poor value based on its PE Ratio (40.6x) compared to the CN market (34.5x).


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate 002252's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: 002252 is good value based on its PB Ratio (1.9x) compared to the CN Biotechs industry average (6.1x).


Future Growth

How is Shanghai RAAS Blood Products forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Shanghai RAAS Blood Products has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Past Performance

How has Shanghai RAAS Blood Products performed over the past 5 years?

-28.9%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: 002252 has high quality earnings.

Growing Profit Margin: 002252's current net profit margins (40.5%) are higher than last year (16.5%).


Past Earnings Growth Analysis

Earnings Trend: 002252's earnings have declined by 28.9% per year over the past 5 years.

Accelerating Growth: 002252's earnings growth over the past year (186.7%) exceeds its 5-year average (-28.9% per year).

Earnings vs Industry: 002252 earnings growth over the past year (186.7%) exceeded the Biotechs industry 16.3%.


Return on Equity

High ROE: 002252's Return on Equity (4.2%) is considered low.


Financial Health

How is Shanghai RAAS Blood Products's financial position?


Financial Position Analysis

Short Term Liabilities: 002252's short term assets (CN¥5.2B) exceed its short term liabilities (CN¥240.0M).

Long Term Liabilities: 002252's short term assets (CN¥5.2B) exceed its long term liabilities (CN¥40.5M).


Debt to Equity History and Analysis

Debt Level: 002252's debt to equity ratio (0.03%) is considered satisfactory.

Reducing Debt: 002252's debt to equity ratio has reduced from 3.5% to 0.03% over the past 5 years.

Debt Coverage: 002252's debt is well covered by operating cash flow (12370.2%).

Interest Coverage: 002252 earns more interest than it pays, so coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Shanghai RAAS Blood Products's current dividend yield, its reliability and sustainability?

0.14%

Current Dividend Yield


Dividend Yield vs Market

Notable Dividend: 002252's dividend (0.14%) isn’t notable compared to the bottom 25% of dividend payers in the CN market (0.42%).

High Dividend: 002252's dividend (0.14%) is low compared to the top 25% of dividend payers in the CN market (1.79%).


Stability and Growth of Payments

Stable Dividend: 002252 is not paying a notable dividend for the CN market, therefore no need to check if payments are stable.

Growing Dividend: 002252 is not paying a notable dividend for the CN market, therefore no need to check if payments are increasing.


Current Payout to Shareholders

Dividend Coverage: 002252 is not paying a notable dividend for the CN market.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of 002252's dividend in 3 years as they are not forecast to pay a notable one for the CN market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

8.0yrs

Average management tenure


CEO

Jun Xu

no data

Tenure

CN¥2,678,700

Compensation

Mr. Jun Xu serves as General Manager and Director of Shanghai RAAS Blood Products Co., Ltd Mr. Jun Xu served as Deputy General Manager of Shanghai RAAS Blood Products Co., Ltd. since April 19, 2013.


Leadership Team

Experienced Management: 002252's management team is seasoned and experienced (8 years average tenure).


Board Members

Experienced Board: 002252's board of directors are considered experienced (8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Shanghai RAAS Blood Products Co., Ltd.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Shanghai RAAS Blood Products Co., Ltd.
  • Ticker: 2252
  • Exchange: SZSE
  • Founded: 1988
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: CN¥49.343b
  • Shares outstanding: 6.74b
  • Website: https://www.raas-corp.com

Number of Employees


Location

  • Shanghai RAAS Blood Products Co., Ltd.
  • No. 2009, Wangyuan Road
  • Fengxian District
  • Shanghai
  • 201401
  • China

Listings


Biography

Shanghai RAAS Blood Products Co., Ltd. manufactures and distributes blood products in China and internationally. It offers human albumin, human immunoglobulin, coagulation factor, and other products. The c...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2021/04/11 09:04
End of Day Share Price2021/04/09 00:00
Earnings2020/09/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.